REFERENCES
2. Mattson MP, Arumugam TV. Hallmarks of brain aging: adaptive and pathological modification by metabolic states. Cell Metab 2018;27:1176-99.
3. Emamzadeh FN, Surguchov A. Parkinson’s disease: biomarkers, treatment, and risk factors. Front Neurosci 2018;12:612.
5. Zheng X, Boyer L, Jin M, et al. Metabolic reprogramming during neuronal differentiation from aerobic glycolysis to neuronal oxidative phosphorylation. Elife 2016;5:e13374.
6. Bélanger M, Allaman I, Magistretti PJ. Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. Cell Metab 2011;14:724-38.
7. Sá JV, Kleiderman S, Brito C, et al. Quantification of metabolic rearrangements during neural stem cells differentiation into astrocytes by metabolic flux analysis. Neurochem Res 2017;42:244-53.
8. Weightman Potter PG, Vlachaki Walker JM, Robb JL, et al. Basal fatty acid oxidation increases after recurrent low glucose in human primary astrocytes. Diabetologia 2019;62:187-98.
9. Mann K, Deny S, Ganguli S, Clandinin TR. Coupling of activity, metabolism and behaviour across the Drosophila brain. Nature 2021;593:244-8.
10. Beard E, Lengacher S, Dias S, Magistretti PJ, Finsterwald C. Astrocytes as key regulators of brain energy metabolism: new therapeutic perspectives. Front Physiol 2021;12:825816.
11. Yakushev I, Schreckenberger M, Müller MJ, et al. Functional implications of hippocampal degeneration in early Alzheimer’s disease: a combined DTI and PET study. Eur J Nucl Med Mol Imaging 2011;38:2219-27.
12. Bateman RJ, Xiong C, Benzinger TLS, et al; Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 2012;367:795-804.
13. Matthews DC, Lerman H, Lukic A, et al. FDG PET Parkinson’s disease-related pattern as a biomarker for clinical trials in early stage disease. Neuroimage Clin 2018;20:572-9.
14. Ciarmiello A, Cannella M, Lastoria S, et al. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington’s disease. J Nucl Med 2006;47:215-22.
15. Cistaro A, Valentini MC, Chiò A, et al. Brain hypermetabolism in amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar onset. Eur J Nucl Med Mol Imaging 2012;39:251-9.
16. Diehl-Schmid J, Licata A, Goldhardt O, et al; FTLDc Study Group. FDG-PET underscores the key role of the thalamus in frontotemporal lobar degeneration caused by C9ORF72 mutations. Transl Psychiatry 2019;9:54.
17. Ionescu-Tucker A, Cotman CW. Emerging roles of oxidative stress in brain aging and Alzheimer’s disease. Neurobiol Aging 2021;107:86-95.
18. Kishida KT, Klann E. Sources and targets of reactive oxygen species in synaptic plasticity and memory. Antioxid Redox Signal 2007;9:233-44.
19. Trist BG, Hare DJ, Double KL. Oxidative stress in the aging substantia nigra and the etiology of Parkinson’s disease. Aging Cell 2019;18:e13031.
20. Pandya JD, Grondin R, Yonutas HM, et al. Decreased mitochondrial bioenergetics and calcium buffering capacity in the basal ganglia correlates with motor deficits in a nonhuman primate model of aging. Neurobiol Aging 2015;36:1903-13.
21. Alqahtani T, Deore SL, Kide AA, et al. Mitochondrial dysfunction and oxidative stress in Alzheimer’s disease, and Parkinson’s disease, Huntington’s disease and Amyotrophic Lateral Sclerosis - an updated review. Mitochondrion 2023;71:83-92.
22. Murray TE, Richards CM, Robert-Gostlin VN, Bernath AK, Lindhout IA, Klegeris A. Potential neurotoxic activity of diverse molecules released by astrocytes. Brain Res Bull 2022;189:80-101.
23. Vicente-Gutierrez C, Bonora N, Bobo-Jimenez V, et al. Astrocytic mitochondrial ROS modulate brain metabolism and mouse behaviour. Nat Metab 2019;1:201-11.
24. Miao J, Chen L, Pan X, Li L, Zhao B, Lan J. Microglial metabolic reprogramming: emerging insights and therapeutic strategies in neurodegenerative diseases. Cell Mol Neurobiol 2023;43:3191-210.
25. Traxler L, Lagerwall J, Eichhorner S, Stefanoni D, D’Alessandro A, Mertens J. Metabolism navigates neural cell fate in development, aging and neurodegeneration. Dis Model Mech 2021;14:dmm048993.
26. Chamberlain KA, Sheng ZH. Mechanisms for the maintenance and regulation of axonal energy supply. J Neurosci Res 2019;97:897-913.
27. Shan L, Zhang T, Fan K, Cai W, Liu H. Astrocyte-neuron signaling in synaptogenesis. Front Cell Dev Biol 2021;9:680301.
28. Yang K, Wu Z, Long J, et al. White matter changes in Parkinson’s disease. NPJ Parkinsons Dis 2023;9:150.
29. Depp C, Sun T, Sasmita AO, et al. Myelin dysfunction drives amyloid-β deposition in models of Alzheimer’s disease. Nature 2023;618:349-57.
30. Takahashi S. Metabolic contribution and cerebral blood flow regulation by astrocytes in the neurovascular unit. Cells 2022;11:813.
31. Nippert AR, Chiang PP, Del Franco AP, Newman EA. Astrocyte regulation of cerebral blood flow during hypoglycemia. J Cereb Blood Flow Metab 2022;42:1534-46.
32. Chen Z, Yuan Z, Yang S, et al. Brain energy metabolism: astrocytes in neurodegenerative diseases. CNS Neurosci Ther 2023;29:24-36.
33. Briski KP, Ibrahim MMH, Mahmood ASMH, Alshamrani AA. Norepinephrine regulation of ventromedial hypothalamic nucleus astrocyte glycogen metabolism. Int J Mol Sci 2021;22:759.
34. Pellerin L, Magistretti PJ. Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc Natl Acad Sci U S A 1994;91:10625-9.
35. Benarroch EE. Neuron-astrocyte interactions: partnership for normal function and disease in the central nervous system. Mayo Clin Proc 2005;80:1326-38.
36. Cortes-Campos C, Elizondo R, Carril C, et al. MCT2 expression and lactate influx in anorexigenic and orexigenic neurons of the arcuate nucleus. PLoS One 2013;8:e62532.
37. Roumes H, Jollé C, Blanc J, et al. Lactate transporters in the rat barrel cortex sustain whisker-dependent BOLD fMRI signal and behavioral performance. Proc Natl Acad Sci U S A 2021;118:e2112466118.
38. Muraleedharan R, Gawali MV, Tiwari D, et al. AMPK-regulated astrocytic lactate shuttle plays a non-cell-autonomous role in neuronal survival. Cell Rep 2020;32:108092.
39. Boisvert MM, Erikson GA, Shokhirev MN, Allen NJ. The aging astrocyte transcriptome from multiple regions of the mouse brain. Cell Rep 2018;22:269-85.
40. Ebert D, Haller RG, Walton ME. Energy contribution of octanoate to intact rat brain metabolism measured by 13C nuclear magnetic resonance spectroscopy. J Neurosci 2003;23:5928-35.
41. Cashikar AG, Toral-Rios D, Timm D, et al. Regulation of astrocyte lipid metabolism and ApoE secretionby the microglial oxysterol, 25-hydroxycholesterol. J Lipid Res 2023;64:100350.
42. van Deijk AF, Camargo N, Timmerman J, et al. Astrocyte lipid metabolism is critical for synapse development and function in vivo. Glia 2017;65:670-82.
43. Ioannou MS, Jackson J, Sheu SH, et al. Neuron-astrocyte metabolic coupling protects against activity-induced fatty acid toxicity. Cell 2019;177:1522-35.e14.
44. Wright-Jin EC, Gutmann DH. Microglia as dynamic cellular mediators of brain function. Trends Mol Med 2019;25:967-79.
45. Bernier LP, York EM, Kamyabi A, Choi HB, Weilinger NL, MacVicar BA. Microglial metabolic flexibility supports immune surveillance of the brain parenchyma. Nat Commun 2020;11:1559.
46. Nagy AM, Fekete R, Horvath G, et al. Versatility of microglial bioenergetic machinery under starving conditions. Biochim Biophys Acta Bioenerg 2018;1859:201-14.
47. Sabogal-Guáqueta AM, Marmolejo-Garza A, Trombetta-Lima M, et al. Species-specific metabolic reprogramming in human and mouse microglia during inflammatory pathway induction. Nat Commun 2023;14:6454.
48. Dienel GA. Brain glucose metabolism: integration of energetics with function. Physiol Rev 2019;99:949-1045.
49. Tawbeh A, Gondcaille C, Trompier D, Savary S. Peroxisomal ABC transporters: an update. Int J Mol Sci 2021;22:6093.
50. Huang SC, Smith AM, Everts B, et al. Metabolic reprogramming mediated by the mTORC2-IRF4 signaling axis is essential for macrophage alternative activation. Immunity 2016;45:817-30.
51. Van den Bossche J, O’Neill LA, Menon D. Macrophage immunometabolism: where are we (going)? Trends Immunol 2017;38:395-406.
52. Vats D, Mukundan L, Odegaard JI, et al. Oxidative metabolism and PGC-1β attenuate macrophage-mediated inflammation. Cell Metab 2006;4:13-24.
53. Paolicelli RC, Bolasco G, Pagani F, et al. Synaptic pruning by microglia is necessary for normal brain development. Science 2011;333:1456-8.
54. Drummond RA, Swamydas M, Oikonomou V, et al. CARD9+ microglia promote antifungal immunity via IL-1β- and CXCL1-mediated neutrophil recruitment. Nat Immunol 2019;20:559-70.
55. Huang X, Guo M, Zhang Y, et al. Microglial IL-1RA ameliorates brain injury after ischemic stroke by inhibiting astrocytic CXCL1-mediated neutrophil recruitment and microvessel occlusion. Glia 2023;71:1607-25.
56. Hsieh CF, Liu CK, Lee CT, Yu LE, Wang JY. Acute glucose fluctuation impacts microglial activity, leading to inflammatory activation or self-degradation. Sci Rep 2019;9:840.
57. Paolicelli RC, Sierra A, Stevens B, et al. Microglia states and nomenclature: a field at its crossroads. Neuron 2022;110:3458-83.
58. Tagliatti E, Desiato G, Mancinelli S, et al. Trem2 expression in microglia is required to maintain normal neuronal bioenergetics during development. Immunity 2024;57:86-105.e9.
59. Cserép C, Pósfai B, Lénárt N, et al. Microglia monitor and protect neuronal function through specialized somatic purinergic junctions. Science 2020;367:528-37.
60. Joshi AU, Mochly-Rosen D. Mortal engines: mitochondrial bioenergetics and dysfunction in neurodegenerative diseases. Pharmacol Res 2018;138:2-15.
61. García-Cáceres C, Balland E, Prevot V, et al. Role of astrocytes, microglia, and tanycytes in brain control of systemic metabolism. Nat Neurosci 2019;22:7-14.
62. Henn RE, Guo K, Elzinga SE, et al. Single-cell RNA sequencing identifies hippocampal microglial dysregulation in diet-induced obesity. iScience 2023;26:106164.
63. Resnick SM, Pham DL, Kraut MA, Zonderman AB, Davatzikos C. Longitudinal magnetic resonance imaging studies of older adults: a shrinking brain. J Neurosci 2003;23:3295-301.
64. Driscoll I, Davatzikos C, An Y, et al. Longitudinal pattern of regional brain volume change differentiates normal aging from MCI. Neurology 2009;72:1906-13.
65. Fjell AM, McEvoy L, Holland D, Dale AM, Walhovd KB; Alzheimer’s Disease Neuroimaging Initiative. What is normal in normal aging? Effects of aging, amyloid and Alzheimer’s disease on the cerebral cortex and the hippocampus. Prog Neurobiol 2014;117:20-40.
66. Manard M, Bahri MA, Salmon E, Collette F. Relationship between grey matter integrity and executive abilities in aging. Brain Res 2016;1642:562-80.
67. Liu H, Wang L, Geng Z, et al. A voxel-based morphometric study of age- and sex-related changes in white matter volume in the normal aging brain. Neuropsychiatr Dis Treat 2016;12:453-65.
68. Kwak K, Giovanello KS, Bozoki A, Styner M, Dayan E; Alzheimer’s Disease Neuroimaging Initiative. Subtyping of mild cognitive impairment using a deep learning model based on brain atrophy patterns. Cell Rep Med 2021;2:100467.
69. Dienel GA, Rothman DL. Reevaluation of astrocyte-neuron energy metabolism with astrocyte volume fraction correction: impact on cellular glucose oxidation rates, glutamate-glutamine cycle energetics, glycogen levels and utilization rates vs. exercising muscle, and Na+/K+ pumping rates. Neurochem Res 2020;45:2607-30.
70. Boley N, Patil S, Garnett EO, et al. Association between gray matter volume variations and energy utilization in the brain: implications for developmental stuttering. J Speech Lang Hear Res 2021;64:2317-24.
71. Raiko JRH, Tuulari JJ, Saari T, et al. Associations between brain gray matter volumes and adipose tissue metabolism in healthy adults. Obesity 2021;29:543-9.
72. Thambisetty M, Beason-Held LL, An Y, et al. Impaired glucose tolerance in midlife and longitudinal changes in brain function during aging. Neurobiol Aging 2013;34:2271-6.
73. Vagnoni A, Hoffmann PC, Bullock SL. Reducing Lissencephaly-1 levels augments mitochondrial transport and has a protective effect in adult Drosophila neurons. J Cell Sci 2016;129:178-90.
74. Yarchoan M, Toledo JB, Lee EB, et al. Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer’s disease and tauopathies. Acta Neuropathol 2014;128:679-89.
75. Mattson MP. Roles of the lipid peroxidation product 4-hydroxynonenal in obesity, the metabolic syndrome, and associated vascular and neurodegenerative disorders. Exp Gerontol 2009;44:625-33.
76. Delgado T, Petralia RS, Freeman DW, et al. Comparing 3D ultrastructure of presynaptic and postsynaptic mitochondria. Biol Open 2019;8:bio044834.
77. Faitg J, Lacefield C, Davey T, et al. 3D neuronal mitochondrial morphology in axons, dendrites, and somata of the aging mouse hippocampus. Cell Rep 2021;36:109509.
78. Salvadores N, Sanhueza M, Manque P, Court FA. Axonal degeneration during aging and its functional role in neurodegenerative disorders. Front Neurosci 2017;11:451.
79. Stahon KE, Bastian C, Griffith S, Kidd GJ, Brunet S, Baltan S. Age-related changes in axonal and mitochondrial ultrastructure and function in white matter. J Neurosci 2016;36:9990-10001.
80. Stargardt A, Swaab DF, Bossers K. Storm before the quiet: neuronal hyperactivity and Aβ in the presymptomatic stages of Alzheimer’s disease. Neurobiol Aging 2015;36:1-11.
81. Lockwood CT, Duffy CJ. Hyperexcitability in aging is lost in Alzheimer’s: what is all the excitement about? Cereb Cortex 2020;30:5874-84.
82. Goyal MS, Vlassenko AG, Blazey TM, et al. Loss of brain aerobic glycolysis in normal human aging. Cell Metab 2017;26:353-60.e3.
83. Cotto B, Natarajaseenivasan K, Langford D. Astrocyte activation and altered metabolism in normal aging, age-related CNS diseases, and HAND. J Neurovirol 2019;25:722-33.
84. Boumezbeur F, Mason GF, de Graaf RA, et al. Altered brain mitochondrial metabolism in healthy aging as assessed by in vivo magnetic resonance spectroscopy. J Cereb Blood Flow Metab 2010;30:211-21.
85. Clarke LE, Liddelow SA, Chakraborty C, Münch AE, Heiman M, Barres BA. Normal aging induces A1-like astrocyte reactivity. Proc Natl Acad Sci U S A 2018;115:E1896-905.
86. Jiang T, Cadenas E. Astrocytic metabolic and inflammatory changes as a function of age. Aging Cell 2014;13:1059-67.
87. McNair LM, Andersen JV, Waagepetersen HS. Stable isotope tracing reveals disturbed cellular energy and glutamate metabolism in hippocampal slices of aged male mice. Neurochem Int 2023;171:105626.
88. de Ceglia R, Ledonne A, Litvin DG, et al. Specialized astrocytes mediate glutamatergic gliotransmission in the CNS. Nature 2023;622:120-9.
89. Mela V, Mota BC, Milner M, et al. Exercise-induced re-programming of age-related metabolic changes in microglia is accompanied by a reduction in senescent cells. Brain Behav Immun 2020;87:413-28.
90. Minhas PS, Latif-Hernandez A, McReynolds MR, et al. Restoring metabolism of myeloid cells reverses cognitive decline in ageing. Nature 2021;590:122-8.
91. Hickman SE, Kingery ND, Ohsumi TK, et al. The microglial sensome revealed by direct RNA sequencing. Nat Neurosci 2013;16:1896-905.
92. Lee S, Devanney NA, Golden LR, et al. APOE modulates microglial immunometabolism in response to age, amyloid pathology, and inflammatory challenge. Cell Rep 2023;42:112196.
93. Victor MB, Leary N, Luna X, et al. Lipid accumulation induced by APOE4 impairs microglial surveillance of neuronal-network activity. Cell Stem Cell 2022;29:1197-212.e8.
94. Marschallinger J, Iram T, Zardeneta M, et al. Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain. Nat Neurosci 2020;23:194-208.
95. Yen JJ, Yu II. The role of ApoE-mediated microglial lipid metabolism in brain aging and disease. Immunometabolism 2023;5:e00018.
96. Ross GW, Petrovitch H, Abbott RD, et al. Parkinsonian signs and substantia nigra neuron density in decendents elders without PD. Ann Neurol 2004;56:532-9.
97. Vanitallie TB. Parkinson disease: primacy of age as a risk factor for mitochondrial dysfunction. Metabolism 2008;57 Suppl 2:S50-5.
98. Rudow G, O’Brien R, Savonenko AV, et al. Morphometry of the human substantia nigra in ageing and Parkinson’s disease. Acta Neuropathol 2008;115:461-70.
99. Elstner M, Morris CM, Heim K, et al. Expression analysis of dopaminergic neurons in Parkinson’s disease and aging links transcriptional dysregulation of energy metabolism to cell death. Acta Neuropathol 2011;122:75-86.
100. Keeney PM, Xie J, Capaldi RA, Bennett JP Jr. Parkinson’s disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci 2006;26:5256-64.
101. Sherer TB, Betarbet R, Testa CM, et al. Mechanism of toxicity in rotenone models of Parkinson’s disease. J Neurosci 2003;23:10756-64.
102. Requejo-Aguilar R, Lopez-Fabuel I, Fernandez E, Martins LM, Almeida A, Bolaños JP. PINK1 deficiency sustains cell proliferation by reprogramming glucose metabolism through HIF1. Nat Commun 2014;5:4514.
103. Pissadaki EK, Bolam JP. The energy cost of action potential propagation in dopamine neurons: clues to susceptibility in Parkinson’s disease. Front Comput Neurosci 2013;7:13.
104. Guzman JN, Sanchez-Padilla J, Wokosin D, et al. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 2010;468:696-700.
105. Xie B, Lin F, Ullah K, et al. A newly discovered neurotoxin ADTIQ associated with hyperglycemia and Parkinson’s disease. Biochem Biophys Res Commun 2015;459:361-6.
106. Chinta SJ, Andersen JK. Redox imbalance in Parkinson’s disease. Biochim Biophys Acta 2008;1780:1362-7.
107. Huang M, Lou D, Charli A, et al. Mitochondrial dysfunction-induced H3K27 hyperacetylation perturbs enhancers in Parkinson’s disease. JCI Insight 2021;6:e138088.
108. Fanning S, Haque A, Imberdis T, et al. Lipidomic analysis of α-synuclein neurotoxicity identifies stearoyl CoA desaturase as a target for parkinson treatment. Mol Cell 2019;73:1001-14.e8.
109. Zhao C, Tu J, Wang C, et al. Lysophosphatidylcholine binds α-synuclein and prevents its pathological aggregation. Natl Sci Rev 2024;11:nwae182.
110. Mazzio E, Soliman KF. The role of glycolysis and gluconeogenesis in the cytoprotection of neuroblastoma cells against 1-methyl 4-phenylpyridinium ion toxicity. Neurotoxicology 2003;24:137-47.
111. Fernandes HJR, Patikas N, Foskolou S, et al. Single-cell transcriptomics of Parkinson’s disease human in vitro models reveals dopamine neuron-specific stress responses. Cell Rep 2020;33:108263.
112. Powers R, Lei S, Anandhan A, et al. Metabolic investigations of the molecular mechanisms associated with Parkinson’s disease. Metabolites 2017;7:22.
113. Giordano S, Lee J, Darley-Usmar VM, Zhang J. Distinct effects of rotenone, 1-methyl-4-phenylpyridinium and 6-hydroxydopamine on cellular bioenergetics and cell death. PLoS One 2012;7:e44610.
114. Lei S, Zavala-Flores L, Garcia-Garcia A, et al. Alterations in energy/redox metabolism induced by mitochondrial and environmental toxins: a specific role for glucose-6-phosphate-dehydrogenase and the pentose phosphate pathway in paraquat toxicity. ACS Chem Biol 2014;9:2032-48.
115. Butler EK, Voigt A, Lutz AK, et al. The mitochondrial chaperone protein TRAP1 mitigates α-synuclein toxicity. PLoS Genet 2012;8:e1002488.
116. Rothman SM, Griffioen KJ, Fishbein KW, et al. Metabolic abnormalities and hypoleptinemia in α-synuclein A53T mutant mice. Neurobiol Aging 2014;35:1153-61.
117. Müftüoglu M, Elibol B, Dalmizrak O, et al. Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations. Mov Disord 2004;19:544-8.
118. Wang HL, Chou AH, Wu AS, et al. PARK6 PINK1 mutants are defective in maintaining mitochondrial membrane potential and inhibiting ROS formation of substantia nigra dopaminergic neurons. Biochim Biophys Acta 2011;1812:674-84.
119. Niu J, Yu M, Wang C, Xu Z. Leucine-rich repeat kinase 2 disturbs mitochondrial dynamics via dynamin-like protein. J Neurochem 2012;122:650-8.
120. Requejo-Aguilar R, Lopez-Fabuel I, Jimenez-Blasco D, Fernandez E, Almeida A, Bolaños JP. DJ1 represses glycolysis and cell proliferation by transcriptionally up-regulating Pink1. Biochem J 2015;467:303-10.
121. Larsen NJ, Ambrosi G, Mullett SJ, Berman SB, Hinkle DA. DJ-1 knock-down impairs astrocyte mitochondrial function. Neuroscience 2011;196:251-64.
122. Kim JM, Cha SH, Choi YR, Jou I, Joe EH, Park SM. DJ-1 deficiency impairs glutamate uptake into astrocytes via the regulation of flotillin-1 and caveolin-1 expression. Sci Rep 2016;6:28823.
123. Cole NB, Murphy DD, Grider T, Rueter S, Brasaemle D, Nussbaum RL. Lipid droplet binding and oligomerization properties of the Parkinson’s disease protein alpha-synuclein. J Biol Chem 2002;277:6344-52.
124. Kim S, Pajarillo E, Nyarko-Danquah I, Aschner M, Lee E. Role of astrocytes in Parkinson’s disease associated with genetic mutations and neurotoxicants. Cells 2023;12:622.
125. Choi I, Kim J, Jeong HK, et al. PINK1 deficiency attenuates astrocyte proliferation through mitochondrial dysfunction, reduced AKT and increased p38 MAPK activation, and downregulation of EGFR. Glia 2013;61:800-12.
126. Cha SH, Choi YR, Heo CH, et al. Loss of parkin promotes lipid rafts-dependent endocytosis through accumulating caveolin-1: implications for Parkinson’s disease. Mol Neurodegener 2015;10:63.
127. Sonninen TM, Hämäläinen RH, Koskuvi M, et al. Metabolic alterations in Parkinson’s disease astrocytes. Sci Rep 2020;10:14474.
128. Castagnet PI, Golovko MY, Barceló-Coblijn GC, Nussbaum RL, Murphy EJ. Fatty acid incorporation is decreased in astrocytes cultured from alpha-synuclein gene-ablated mice. J Neurochem 2005;94:839-49.
129. Alecu I, Bennett SAL. Dysregulated lipid metabolism and its role in α-synucleinopathy in Parkinson’s disease. Front Neurosci 2019;13:328.
130. Russ K, Teku G, Bousset L, et al. TNF-α and α-synuclein fibrils differently regulate human astrocyte immune reactivity and impair mitochondrial respiration. Cell Rep 2021;34:108895.
131. Halliday GM, Stevens CH. Glia: initiators and progressors of pathology in Parkinson’s disease. Mov Disord 2011;26:6-17.
132. Peng Y, He J, Xiang H, et al. Potential impact of hypoxic astrocytes on the aggravation of depressive symptoms in Parkinson’s disease. J Mol Neurosci 2024;74:28.
133. Libro R, Bramanti P, Mazzon E. The role of the Wnt canonical signaling in neurodegenerative diseases. Life Sci 2016;158:78-88.
134. Vallée A, Lecarpentier Y, Vallée JN. Circadian rhythms and energy metabolism reprogramming in Parkinson’s disease. Curr Issues Mol Biol 2019;31:21-44.
135. L’episcopo F, Serapide MF, Tirolo C, et al. A Wnt1 regulated Frizzled-1/β-Catenin signaling pathway as a candidate regulatory circuit controlling mesencephalic dopaminergic neuron-astrocyte crosstalk: Therapeutical relevance for neuron survival and neuroprotection. Mol Neurodegener 2011;6:49.
136. Yang S, Qin C, Hu ZW, et al. Microglia reprogram metabolic profiles for phenotype and function changes in central nervous system. Neurobiol Dis 2021;152:105290.
137. Pajares M, I Rojo A, Manda G, Boscá L, Cuadrado A. Inflammation in Parkinson’s disease: mechanisms and therapeutic implications. Cells 2020;9:1687.
138. Colonna M, Butovsky O. Microglia function in the central nervous system during health and neurodegeneration. Annu Rev Immunol 2017;35:441-68.
139. Lavisse S, Goutal S, Wimberley C, et al. Increased microglial activation in patients with Parkinson disease using [18F]-DPA714 TSPO PET imaging. Parkinsonism Relat Disord 2021;82:29-36.
140. Gu R, Zhang F, Chen G, et al. Clk1 deficiency promotes neuroinflammation and subsequent dopaminergic cell death through regulation of microglial metabolic reprogramming. Brain Behav Immun 2017;60:206-19.
141. Tu D, Gao Y, Yang R, Guan T, Hong JS, Gao HM. The pentose phosphate pathway regulates chronic neuroinflammation and dopaminergic neurodegeneration. J Neuroinflammation 2019;16:255.
142. Qiao H, He X, Zhang Q, et al. Alpha-synuclein induces microglial migration via PKM2-dependent glycolysis. Int J Biol Macromol 2019;129:601-7.
143. Cheng SC, Quintin J, Cramer RA, et al. mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science 2014;345:1250684.
144. Baik SH, Kang S, Lee W, et al. A breakdown in metabolic reprogramming causes microglia dysfunction in Alzheimer’s disease. Cell Metab 2019;30:493-507.e6.
145. Lu J, Wang C, Cheng X, et al. A breakdown in microglial metabolic reprogramming causes internalization dysfunction of α-synuclein in a mouse model of Parkinson’s disease. J Neuroinflammation 2022;19:113.
146. Szwed A, Kim E, Jacinto E. Regulation and metabolic functions of mTORC1 and mTORC2. Physiol Rev 2021;101:1371-426.
147. Brekk OR, Honey JR, Lee S, Hallett PJ, Isacson O. Cell type-specific lipid storage changes in Parkinson’s disease patient brains are recapitulated by experimental glycolipid disturbance. Proc Natl Acad Sci U S A 2020;117:27646-54.
148. Choe CU, Petersen E, Lezius S, et al. Association of lipid levels with motor and cognitive function and decline in advanced Parkinson’s disease in the Mark-PD study. Parkinsonism Relat Disord 2021;85:5-10.
